Diabetes mellitus combined with intracranial aneurysm
Conditions
Interventions
Normal group:None
Simple intracranial aneurysm group (unruptured):None
Diabetes mellitus combined with intracranial aneurysm group (unruptured):None
Simple intracranial aneurysm group (ruptured):None
Diabetes mellitus combined with intracranial aneurysm group (ruptured):None
Sponsors
Affiliated Hospital of Zunyi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Eligible patients, aged between 18 and 70 years, who expressed willingness to participate in the trial after proper communication, were enrolled upon signing an informed consent form. 2.Within 24 hours of symptom onset, all enrolled patients underwent either computed tomography angiography (CTA), digital subtraction angiography (DSA), or magnetic resonance angiography (MRA) to confirm the presence of intracranial aneurysms. 3.Patients with aneurysmal subarachnoid hemorrhage (aSAH) must have a cranial CT scan showing clear signs of subarachnoid hemorrhage. 4.The patient's hospitalization or survival duration exceeds 14 days. 5.Patients with no history of infection, immune system disease, or cancer were included. 6.Patients with normal cardiovascular, respiratory, hepatic, and renal functions were included. 7.Patients with type 2 diabetes mellitus (T2DM) were included if they had a confirmed previous diagnosis of T2DM and fasting blood glucose levels >7.0 mmol/L or HbA1c >6.5%. 8.All included patients had no prior history of hypertension or long-term (=6 months) blood pressure consistently controlled below <140/90mmHg.
Exclusion criteria
Exclusion criteria: 1. Exclude patients with traumatic subarachnoid hemorrhage, hematologic disorders, hypertensive cerebral hemorrhage with ventricular rupture, smog-related disease, intracranial tumor stroke, pseudoaneurysm, arteriovenous malformation, and other intracranial vascular malformations. 2. Exclude patients with severe cardiac, pulmonary, hepatic, or renal insufficiency. 3. Exclude patients with incomplete clinical information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peripheral blood CCR1 expression;Peripheral blood CD86 expression;Peripheral blood TLR2 expression; | — |
Countries
China
Contacts
Public ContactCao Fang
Affiliated Hospital of Zunyi Medical University
Outcome results
None listed